Advanced Solutions
for Advanced Pathology
LMO2 (SP51)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45316 IMPATH LMO2 RTU R (SP51)
50 Tests
44327 LMO2 RTU R (SP51)
7 ml Ready To Use
44676 LMO2 0,1 R (SP51)
100 µl liquid Concentrated
44677 LMO2 1 R (SP51)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Diffuse large B-cell lymphoma,
Follicular Lymphoma, Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP 2-step Polymer (Universal) or
AP Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
LMO2 is expressed in normal germinal center B-cells and in a subset of lymphomas derived from those cells in addition to bone marrow
hematopoietic precursors and endothelial cells. LMO2 protein expression has also been shown to play an important role in the diagnosis of
diffuse large B-cell lymphomas, regardless of rituximab treatment. It also plays a role in angiogenesis and hematopoiesis. It is weakly expressed
in mantle zone B-cells but not in mantle cell or marginal zone lymphomas. Younes et al. have demonstrated LMO2 expression in 70% of follicular
lymphomas. These data suggest that anti-LMO2 is a useful adjunct in the diagnosis of follicular lymphoma (FL). As LMO2 appears not to be
down regulated in higher grade FL or the interfollicular and diffuse components of FL, its utility in variant immunoarchitectural patterns of FL and
in cases that lack CD10 and BCL2, is similar to that of HGAL. One advantage of anti-LMO2 is its crisp nuclear localization that allows for easier
interpretation than the diffuse cytoplasmic staining pattern of anti-HGAL.
Mature B-cell Lymphomas
LMO2
HGAL
CD20
CD5
CD23
CD10
BCL2
Follicular Lymphoma
+
+
+
-
-
+/-
+/-
Diffuse Large B-cell
Lymphoma
+
+
+
-/+
-
+/-
+
Small Lymphocytic
Lymphoma
-
-
+
+
+
-
+
Mantle Cell Lymphoma
-
-
+
+
-
-
+
Marginal Zone Lymphoma
-
-
+
-
-
-
+
Reference
1. Younes SF, et al. Am J Surg Pathol. 2010; 34:1266-76.
159
